Medical imaging reagents are used in diagnostic applications such as MRI, ultrasound, X-ray, and nuclear imaging for advanced diagnostics and visualization of organs, soft tissues, and bone structures. Advancements in molecular imaging reagents and targeted contrast agents enable to image biological processes at the cellular and molecular levels with high sensitivity and specificity. The global Medical Imaging Reagents Market is estimated to be valued at US$ 11.21 Billion in 2023 and is expected to exhibit a CAGR of 5.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Advancing innovation in molecular imaging reagents to boost the market growth over the forecast period. Molecular imaging allows for personalized medical imaging at cellular and molecular levels with high sensitivity and specificity. Ongoing R&D in molecular imaging reagents, targeted contrast agents, and specialty reagents for advanced applications like nucleic acid, and protein targeted probes. These advancements enable ultrasensitive detection of molecular changes at early disease stages and help monitor therapeutic responses in real-time. Leading players are focusing on developing novel targeted molecular imaging agents for applications in oncology, cardiology, neurology, and other areas which is expected to drive the medical imaging reagents market growth during the forecast period.
Segment Analysis
The global medical imaging reagents market is segmented based on product, application, end user, and region. On the basis of product, contrast media accounts for the largest share in the medical imaging reagents market. Contrast media enhances the visibility of internal body structures during imaging procedures like CT, MRI, ultrasound and X-ray scans. High usage of contrast media for diagnostic purposes across various disease areas such as oncology, cardiology and neurology is driving the growth of this segment.
Key Takeaways
The global Medical Imaging Reagents market is expected to witness high growth. The region of North America dominated the market and is expected to continue its dominance during the forecast period. This can be attributed to well-established healthcare facilities, technological advancements in medical imaging modalities and growing prevalence of chronic diseases.
Key players operating in the Medical Imaging Reagents market are Bayer AG, Bracco SpA, Eli Lilly and Company, General Electric Company (GE Healthcare), among others. Bayer AG offers a comprehensive portfolio of contrast agents, including Xenetix and Gadovist, among others. The company focuses on research and development activities to develop innovative contrast agents.
Europe is also expected to hold a significant share in the market. Presence of major players, favorable reimbursement policies, and government support for research & development drives the growth of the European medical imaging reagents market.
Asia Pacific region is poised to exhibit the highest CAGR during the forecast period. Increasing healthcare expenditure, rising incidences of chronic diseases, growing awareness about diseases diagnosis are factors fueling the market growth in this region.
No comments:
Post a Comment